ABOUT THE THERAPY TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

MINIMALLY INVASIVE ALTERNATIVE FOR SEVERE AORTIC STENOSIS

TAVR Incision Locations

A changing paradigm in the management of patients with severe aortic stenosis, transcatheter aortic valve replacement (TAVR) is a minimally invasive, catheter-based procedure to replace the aortic valve. Prior to TAVR, treatment options were limited to:

  • Temporarily improving valve function and easing symptoms by prescribing medication and performing a BAV procedure
  • Replacing the diseased valve in an open-heart surgery (surgical aortic valve implantation)

TAVR does not require open-heart surgery. Instead, with TAVR, the heart is accessed via an artery. There are three access options:

  1. Transfemoral
  2. Subclavian
  3. Direct aortic

Using imaging and a delivery system, the physician threads the compressed bioprosthetic heart valve through the catheter and positions it within the diseased valve.

After positioning the bioprosthetic valve, the physician begins deploying the valve; the middle image below shows a partially expanded valve. When deployment is complete, the bioprosthetic valve is fully expanded within the diseased native valve.

Compressed bioprosthetic valve within catheter
Bioprosthetic valve partially expanded
Bioprosthetic valve fully expanded within the diseased native valve

After testing the new valve function, the physician removes the catheter and closes the incision.


AN EXCELLENT OPTION WHEN THERE ARE INCREASED RISKS

TAVR may be an excellent option for certain patients with severe symptomatic aortic stenosis who may have increased risks associated with surgical aortic valve implantation (SAVI).1

Without intervention, this patient population's survival rate is approximately 50% at two years.2

The Evolut™ TAVR Platform is the only TAVR platform on the market to demonstrate statistically significant better outcomes in terms of all cause mortality or stroke at 3 years vs. SAVR.3


POTENTIAL BENEFITS

The Evolut TAVR platform’s supra-annular valve design delivers large EOAs (effective orifice area) and low single-digit gradients resulting in industry-leading hemodynamics.

POTENTIAL RISKS

Most medical procedures have risks. The Medtronic TAVR procedure’s most serious risks include:

  • Death
  • Stroke
  • Serious damage to the arteries
  • Serious bleeding
  • Need for permanent pacemaker

THE MEDTRONIC ADVANTAGE

Evolut Pro 29mm Product

Today, TAVR is a proven procedure that can prolong lives.  At Medtronic, we believe it is the choice for patients who can return to an active life.

We've designed the Evolut platform to achieve industry-leading hemodynamics, which are important to younger, more active patients.

We offer outstanding training and resources for your heart teams.

LIFELINE CARDIOVASCULAR TECHNICAL SUPPORT

877-526-7890

rs.cstechsupport@medtronic.com

STAY

INFORMED

Receive email updates about Medtronic TAVR.

SIGN UP

1

Schwartz F, et al. Circulation. 1982; 66:1105-1110.

2

Lester SJ, Heilbron B, Gin K, Dodek A, Jue J. The natural history and rate of progression of aortic stenosis. Chest. 1998 Apr;113(4):1109-14. Review. PubMed PMID: 9554654.

3

Deeb GM, et al, J Am Coll Cardiol. 2016 Jun 7;67(22):2565-74. doi: 10.1016/j.jacc.2016.03.506. Epub 2016 Apr 3.